Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$66.02 USD
-2.91 (-4.22%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $66.02 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.02 USD
-2.91 (-4.22%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $66.02 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Edwards Lifesciences (EW) Down 3.3% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp Grows on Solid Diagnostics, Currency Woes a Drag
by Zacks Equity Research
Although LabCorp's (LH) Covance drug development business puts up a dull performance, the market is upbeat about its Diagnostics business, which has recently displayed a solid show.
Henry Schein's Merritt Buyout to Boost U.S. Veterinary Arm
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Merritt Veterinary supplies will brace its existing U.S. animal health business, particularly in the southeastern United States.
LabCorp & Interpace Extend Deal, Boost Cancer Portfolio
by Zacks Equity Research
LabCorp's (LH) agreement to offer Interpace Diagnostics' molecular tests, ThyGenX and ThyraMIR gets renewed and extended for another two years.
C. R. Bard's (BCR) LUTONIX 035 Gets FDA Pre-Market Approval
by Zacks Equity Research
The early market acceptance of the LUTONIX platform has been impressive and C. R. Bard (BCR) is likely to witness an expanded adoption of this technology as the market continues to mature.
Hill-Rom (HRC) Stock Down With Dull Patient Support Systems
by Zacks Equity Research
Hill-Rom's (HRC) Patient Support Systems revenue decreases due to the adverse effect of the WatchChild and Architectural Products divestitures along with lower rental revenues.
LabCorp's $1.2 Billion Chiltern Buyout Gets FTC Approval
by Zacks Equity Research
The Federal Trade Commission (FTC) has granted LabCorp's (LH) request for an early closure of Chiltern's acquisition under HSR Act.
Chemed (CHE) on Growth Track With VITAS & Roto-Rooter Arms
by Zacks Equity Research
The raised outlook for both Roto-Rooter unit and the bottom line indicate Chemed's (CHE) estimate of improved operating results in the upcoming quarters.
Align Technology-Patterson Dental Deal Expands iTero Reach
by Zacks Equity Research
Align Technology (ALGN) progresses with a slew of developments in the scanners and services segment.
LabCorp to Add ChromaDex's Arm, Inorganic Expansion On Track
by Zacks Equity Research
LabCorp's (LH) decision to buy the analytical testing services arm of ChromaDex should fortify its Covance Food Solutions business.
Thermo Fisher's Patheon Buyout Gains Antitrust Clearance
by Zacks Equity Research
Thermo Fisher (TMO) gets antitrust clearance to move a step closer toward completion of Patheon acquisition.
Bull of the Day: Edwards Lifesciences (EW)
by Kevin Cook
The world leader in non-surgical heart valve replacement keeps the "beat and raise" going with innovation and execution
Here's Why Investors Should Buy Amedisys (AMED) Right Now
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Align Technology's Invisalign Sales Strong Amid Margin Woes
by Zacks Equity Research
Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.
LabCorp Partners OmniSeq to Grow in Immuno-Oncology Space
by Zacks Equity Research
LabCorp (LH) decides to distribute OmniSeq's molecular diagnostics assays in the United States and beyond to grow in immuno-oncology space.
CVS Health (CVS) Releases Encouraging Flu Shot Survey Data
by Zacks Equity Research
CVS Health's (CVS) survey on flu vaccination came up with positive outcome. The data confirms untapped opportunities in the flu vaccine market.
Here's Why Investors Should Buy BioTelemetry (BEAT) Now
by Zacks Equity Research
BioTelemetry's (BEAT) buyout of LifeWatch AG has expanded its product portfolio and customer base in the cardiac monitoring and diagnostic services space.
Zacks.com featured highlights: SP Plus Corp, Edwards Lifesciences, Magna International and NVIDIA
by Zacks Equity Research
Zacks.com featured highlights: SP Plus Corp, Edwards Lifesciences, Magna International and NVIDIA
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.
4 Stocks to Buy as Q2 Earnings Season Nears Close
by Tirthankar Chakraborty
Earnings growth is considered to be the most significant variable in influencing the share price.
Accelerate Diagnostics (AXDX) In Focus: Stock Rises 5.1%
by Zacks Equity Research
Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise more than 5% on the day.
Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics
by Zacks Equity Research
Fluidigm (FLDM) has licensed rights to commercialize the cystic fibrosis transmembrane conductance regulator. The company is focused on improving its Juno automated microfluidic system.
Allscripts, Elligo Health Enter in Strategic Partnership
by Zacks Equity Research
Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.
Walgreens' (WBA) Research Website to Add Value in Healthcare
by Zacks Equity Research
Walgreens Boots Alliance's (WBA) Center for Health & Wellbeing Research is set to improve patient care and outcomes while reducing health care costs at the same time.
Omnicell Upgrades Web Portal, Grows in Medication Management
by Zacks Equity Research
Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.